Around the Practice: Improving Outcomes in Advanced Prostate Cancer

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

EP1: Polling Questions: Advanced Prostate Cancer

November 19th 2021

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

EP2: Patient Case #1: Treatment Selection in mCNPC

November 19th 2021

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

EP3: Role of conventional imaging vs PSMA-PET in mCNPC

November 24th 2021

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

EP4: Treatment options for high-volume mCNPC

November 24th 2021

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

EP5: Patient Case #2: Choosing Optimal Therapy in mCRPC

December 2nd 2021

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

EP6: Role of PSMA PET Imaging in mCRPC

December 2nd 2021

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

EP7: Sequencing Therapy for mCRPC

December 9th 2021

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

EP8: Optimization of Genetic Testing for mCRPC

December 9th 2021

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.